Publications by authors named "Pablo Umana"

Claim this Profile
P
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.
Marlena Surowka, Diana Darowski, Idil Hutter-Karakoc, Christina Claus, Claudia Ferrara-Koller

MAbs· December 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice.
Nils O'Brien, Joerg P J Mueller, Ann-Marie E Bröske, Jan Attig, Franz Osl

MAbs· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies.
Idil Hutter-Karakoc, Eleni Maria Varypataki, Aparna Neelakandhan, Simone Lang, Vesna Kramar, Pablo Umana

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB.
Christina Claus, Claudia Ferrara-Koller, Johannes Sam, Sabine Lang, Rosmarie Albrecht

Antibodies (Basel)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.
Johannes Sam, Gabrielle Leclercq-Cohen, Samuel Gebhardt, Marlena Surowka, Sylvia Herter

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1-targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer.
Irene Fusi, Clara Serger, Petra Herzig, Markus Germann, Michael T Sandholzer

Sci Transl Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy.
Marcos Garcia-Lacarte, Sara C Grijalba, Javier Melchor, Marién Pascual, Enrique Goñi

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models.
Eneko Garate-Soraluze, Irantzu Serrano-Mendioroz, Leticia Fernández-Rubio, Carlos E De Andrea, Celia Barrio-Alonso, Pablo Umana

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.
Jan Eckmann, Tanja Fauti, Marlene Biehl, Aintzane Zabaleta, Laura Blanco

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 cis-targeted IL-2v in combination with radiotherapy inhibits lung cancer growth and remodels the immune microenvironment.
Céline Godfroid, Jackeline Romero, Sara Labiano, Chia-Hsien Chuang, Andrea Kelemen

J Immunother Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.
Ramona Schlenker, Petra C Schwalie, Steffen Dettling, Tamara Huesser, Anja Irmisch, Pablo Umana

Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.
Annapaola Mariniello, Tahseen H Nasti, Daniel Y Chang, Masao Hashimoto, Sakshi Malik, Pablo Umana

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
Johannes Sam, Thomas Hofer, Christine Kuettel, Christina Claus, Jenny Thom

Blood· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Solange Peters, Eric Angevin, Teresa Alonso-Gordoa, Kristoffer Rohrberg, Ignacio Melero, Pablo Umana

Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The physiological interactome of TCR-like antibody therapeutics in human tissues.
Estelle Marrer-Berger, Annalisa Nicastri, Angelique Augustin, Vesna Kramar, Hanqing Liao

Nat Commun· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.
Anna Spreafico, Eva Muñoz Couselo, Anja Irmisch, Juliana Bessa, George Au-Yeung

Front Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.
Gerulf Hänel, Anne Schönle, Anne-Sophie Neumann, Daniel Nixdorf, Nora Philipp

Leukemia· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies.
Gabrielle Leclercq-Cohen, Nathalie Steinhoff, Llucia Albertí Servera, Sina Nassiri, Sabrina Danilin

Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC.
Jacob Gadwa, Maria Amann, Thomas E Bickett, Michael W Knitz, Laurel B Darragh

Cell Rep Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma.
Benedetta Apollonio, Filomena Spada, Nedyalko Petrov, Domenico Cozzetto, Despoina Papazoglou, Pablo Umana

J Clin Invest· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.
Miles Piper, Maureen Hoen, Laurel B Darragh, Michael W Knitz, Diemmy Nguyen

Cancer Cell· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1.
Javier Sánchez, Valeria Nicolini, Linda Fahrni, Inja Waldhauer, Antje-Christine Walz

AAPS J· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition.
Laura Codarri Deak, Masao Hashimoto, Pablo Umaña, Christian Klein

Oncoimmunology· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ROCKETS - a novel one-for-all toolbox for light sheet microscopy in drug discovery.
Joerg P J Mueller, Michael Dobosz, Nils O'Brien, Nassri Abdoush, Anna Maria Giusti

Front Immunol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8 T cells and reprogramming macrophages.
Mélanie Tichet, Stephan Wullschleger, Agnieszka Chryplewicz, Nadine Fournier, Rachel Marcone

Immunity· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis